Springworks Therapeutics Inc Quick Ratio (SWTX) starting from the first quarter 2025 to first quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Springworks Therapeutics Inc   (NASDAQ: SWTX)

Springworks Therapeutics Inc 's Quick Ratio

SWTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Springworks Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Springworks Therapeutics Inc 's Quick Ratio to 3.5, Quick Ratio remained below Springworks Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 86 other companies have achieved higher Quick Ratio than Springworks Therapeutics Inc in first quarter 2025. While Quick Ratio total ranking in the first quarter 2025 has deteriorated compared to the prior quarter from 185 to 862.

Explain Quick Ratio?
How much Cash & cash equivalents SWTX´s has?
What are SWTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SWTX Quick Ratio (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1
Y / Y Current Liabilities Change 19.37 % 27.91 % 40.43 % 30.04 % 82.55 %
Y / Y Cash & cash equivalent Change -34.06 % -35.73 % -10.84 % -19.47 % -17.34 %
Quick Ratio MRQ 3.5 3.08 5.33 7.04 6.33
SWTX's Total Ranking # 862 # 185 # 471 # 249 # 476
Seq. Current Liabilities Change -17.72 % 41.6 % 29.57 % -20.92 % -11.84 %
Seq. Cash & cash equivalent Change -6.53 % -18.22 % -1.89 % -12.07 % -8.89 %



Quick Ratio first quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 87
Healthcare Sector # 399
Overall Market # 862


Quick Ratio Statistics
High Average Low
36.25 15.27 3.08
(Mar 31 2020)   (Dec 31 2024)




Financial Statements
Springworks Therapeutics Inc 's Current Liabilities $ 82 Millions Visit SWTX's Balance sheet
Springworks Therapeutics Inc 's Cash & cash equivalent $ 288 Millions Visit SWTX's Balance sheet
Source of SWTX's Sales Visit SWTX's Sales by Geography


Cumulative Springworks Therapeutics Inc 's Quick Ratio

SWTX's Quick Ratio for the trailling 12 Months

SWTX Quick Ratio

 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 28.46 % 41.28 % 50.39 % 39.77 % 38.14 %
Y / Y Cash & cash equivalent TTM Growth -25.27 % -21.05 % -16.99 % -23.43 % -13.86 %
Quick Ratio TTM 4.41 5.12 6.16 6.84 7.58
Total Ranking TTM # 2774 # 1274 # 2465 # 2997 # 2970
Seq. Current Liabilities TTM Growth 4.54 % 8.02 % 8.07 % 5.26 % 14.97 %
Seq. Cash & cash equivalent TTM Growth -9.88 % -10.21 % -2.66 % -5.11 % -4.8 %

Quick ratio ranking by company, industry and sector >> Back to SWTX Financial Strength Comparisons >> Go to Compare SWTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q1 2025 to $82.27 millions, cumulative Quick Ratio decreased to 4.41 below the Springworks Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 128 other companies have achieved higher Quick Ratio than Springworks Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2024 from 1274 to 2774.

Explain Quick Ratio?
How much Cash & cash equivalents SWTX´s has?
What are SWTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 129
Healthcare Sector # 757
Within the Market # 2774


trailing twelve months Quick Ratio Statistics
High Average Low
28.61 15.52 4.41
(Sep 30 2021)   (Mar 31 2025)




Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2025 MRQ Cash & cash equivalentMar 31 2025 MRQ Current Liabilities
Allogene Therapeutics Inc   9.33 $ 280.043  Millions$ 30.022  Millions
Neumora Therapeutics Inc   9.13 $ 249.353  Millions$ 27.324  Millions
Black Diamond Therapeutics Inc   9.05 $ 152.400  Millions$ 16.847  Millions
Aligos Therapeutics Inc   8.92 $ 137.861  Millions$ 15.461  Millions
Denali Therapeutics Inc   8.90 $ 817.926  Millions$ 91.877  Millions
Beam Therapeutics Inc   8.62 $ 1,219.952  Millions$ 141.546  Millions
Fate Therapeutics Inc   8.54 $ 240.425  Millions$ 28.159  Millions
Lexeo Therapeutics Inc   8.33 $ 99.831  Millions$ 11.981  Millions
Zura Bio Limited  8.09 $ 170.569  Millions$ 21.092  Millions
Krystal Biotech Inc   7.76 $ 616.846  Millions$ 79.489  Millions
Replimune Group Inc   7.76 $ 483.804  Millions$ 62.362  Millions
Iteos Therapeutics Inc   7.64 $ 520.369  Millions$ 68.097  Millions
Compass Therapeutics Inc   7.56 $ 112.635  Millions$ 14.900  Millions
Molecular Partners Ag  7.50 $ 104.149  Millions$ 13.895  Millions
Autolus Therapeutics Plc  7.35 $ 516.575  Millions$ 70.324  Millions
Caribou Biosciences Inc   7.32 $ 208.465  Millions$ 28.491  Millions
Kyverna Therapeutics Inc   7.29 $ 242.649  Millions$ 33.292  Millions
Atyr Pharma Inc   7.15 $ 76.349  Millions$ 10.683  Millions
Anavex Life Sciences Corp   6.99 $ 115.771  Millions$ 16.552  Millions
Titan Pharmaceuticals Inc   6.97 $ 1.945  Millions$ 0.279  Millions
In8bio Inc   6.91 $ 11.888  Millions$ 1.720  Millions
Leonabio Inc   6.68 $ 36.670  Millions$ 5.492  Millions
Compugen Ltd  6.61 $ 145.640  Millions$ 22.049  Millions
Vir Biotechnology Inc   6.40 $ 879.089  Millions$ 137.286  Millions
Cardiff Oncology Inc   6.35 $ 79.887  Millions$ 12.575  Millions
Ginkgo Bioworks Holdings Inc   6.30 $ 516.922  Millions$ 82.014  Millions
Precision Biosciences Inc  6.23 $ 77.223  Millions$ 12.393  Millions
Tenaya Therapeutics Inc   6.23 $ 88.158  Millions$ 14.152  Millions
Cargo Therapeutics Inc   6.18 $ 318.836  Millions$ 51.552  Millions
Exozymes Inc   5.89 $ 8.511  Millions$ 1.444  Millions

Date modified: 2026-09-26T07:37:50+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.